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Abstract
Background: The dopamine transporter (DAT) plays a critical role in terminating the action of
dopamine by rapid reuptake into the presynaptic neuron. Previous studies have revealed that the
DAT carboxyl terminus (DAT-CT) can directly interact with other cellular proteins and regulate
DAT function and trafficking.
Results:  Here, we have identified that carboxypeptidase E (CPE), a prohormone processing
exopeptidase and sorting receptor for the regulated secretory pathway, interacts with the DAT-
CT and affects DAT function. Mammalian cell lines coexpressing CPE and DAT exhibited increased
DAT-mediated dopamine uptake activity compared to cells expressing DAT alone. Moreover,
coexpression of an interfering DAT-CT minigene inhibited the effects of CPE on DAT. Functional
changes caused by CPE could be attributed to enhanced DAT expression and subsequent increase
in DAT cell surface localization, due to decreased DAT degradation. In addition, CPE association
could reduce the phosphorylation state of DAT on serine residues, potentially leading to reduced
internalization, thus stabilizing plasmalemmal DAT localization.
Conclusion: Taken together, our results reveal a novel role for CPE in the regulation of DAT
trafficking and DAT-mediated DA uptake, which may provide a novel target in the treatment of
dopamine-governed diseases such as drug addiction and obesity.
Background
The dopamine transporter (DAT) is a presynaptic plasma
protein found on dopaminergic nerve terminals that ter-
minates dopamine signaling by rapidly sequestering
dopamine released into the synaptic cleft [1,2]. DAT
belongs to a family of Na+/Cl- dependent transporters
with several other neurotransmitter transporters, includ-
ing norepinephrine, serotonin, GABA, and glycine trans-
porters [2-4]. Dopamine (DA), an essential
neurotransmitter for normal CNS functions including
motor activity, cognition and reward [5,6], which is
involved in numerous neurological disorders including
Parkinson's disease, drug addiction and schizophrenia, is
primarily cleared from the synapse [7]. Moreover, the DAT
has garnered attention because it is the principle target of
widely abused psychostimulants, such as cocaine and
amphetamine [2-4].
Morphological studies reveal that functional DATs are
localized on the plasma membrane of axons, pre-synaptic
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axon terminals, and dendrites of dopaminergic neurons,
with the highest expression in the axonal processes in
striatum and dendrites in ventral tegmental area [8-10].
Specifically, immunoelectron microscopy studies find
that DAT is located peri-synaptically, indicating that trans-
mitter released at the synapse diffuses out of the cleft to be
transported into the terminal [9,11]. Thus, specific target-
ing and presentation of DAT in neurons require efficient
recycling of transporters after internalization or efficient
export of newly synthesized transporters from the endo-
plasmic reticulum (ER), sorting to transport carriers in the
Golgi complex and delivery/retention of transporters at
the presynaptic functional sites. The expression, traffick-
ing and function of DAT are regulated by several factors
including DAT substrates, inhibitors, and a variety of sig-
naling cascades including protein kinases and phos-
phatases [12-14]. Moreover, structure-function analysis
reveals several important amino acid residues or structural
motifs critical for DAT function. The carboxyl terminus
(CT) of human DAT has been demonstrated to be impor-
tant for cell surface expression and proper function of
DAT [7,15,16]. Recent studies using yeast two-hybrid
approaches have successfully identified several proteins
that interact with the DAT carboxyl terminus and influ-
ence DAT trafficking [16-18]. The PDZ domain-contain-
ing protein PICK1, which binds to a type II PDZ binding
site localized at the DAT distal carboxyl termini, increases
the efficiency of ER-to-plasma membrane trafficking of
the transporter [7,16]. Conversely, Hic-5, a LIM domain
containing protein, has also been shown to bind to the
DAT-CT and inhibit DAT localization to the plasma mem-
brane [17]. In addition, our lab has shown that the DAT
CT can also bind to α-synuclein, which stabilizes DAT on
the surface and could accelerate DA-induced oxidative
stress and cell death [18].
The increasing reports of proteins that interact with DAT
[7,19-26] and their roles in the modulation of physiolog-
ical and pathological DAT functions stress the importance
to understand the molecular mechanisms of how these
interaction proteins affect DAT metabolic cycle and traf-
ficking. Here, in an effort to search for candidate proteins
capable of interacting with DAT and affecting DAT traf-
ficking, we identified the protein carboxypeptidase E
(CPE). Biochemical, immunological, and functional
approaches were employed to examine assembly and traf-
ficking properties of DAT with CPE.
Methods
Yeast two-hybrid screening and β-galactosidase assays
PCR was used to generate CPE-activating domain (AD)
fusion constructs in either pACT2 or pGADT7 and bind-
ing domain(BD) fusion constructs with the DAT intracel-
lular amino-terminal (NT: Met1-Lys66), carboxyl-
terminal (CT1: Leu583-Val620), and carboxyl-terminal
fragments (CT2: Glu598-Val620; CT3: Leu583-Pro597) in
pAS2 or pGBKT7. Appropriate pairs of AD and BD con-
structs were cotransformed into the yeast strain Y187
grown at 30°C for 3 days on Leu-/Trp- medium lacking
leucine and tryptophan, followed by assay of lacZ reporter
activation, present downstream of a GAL4 binding
sequence in Y187, as described by the manufacturer
(Clontech). All control transformations were negative for
β-galactosidase activity except for BD/p53 with AD/T anti-
gen, used as a positive control. All constructs were
sequenced to determine appropriate splice fusion and
absence of spurious PCR-generated mutations.
Coimmunoprecipitation, affinity purification (pull-down), 
and Western blotting
Coimmunoprecipitation, affinity pull-down, and Western
blot analyses were performed as previously described [27-
29]. Rat brain striatum (100 mg) or transfected COS-7
cells (~2 × 107) were homogenized in buffer containing
(in mM) 50 Tris-Cl, pH 7.6, 150 NaCl, 2 EDTA, 1 PMSF
plus 1% Igepal CA-630, 0.5 to ~1% sodium deoxycholate,
1% Triton X-100, and protease inhibitor mixture (Sigma);
after being centrifuged at 10,000 × g at 4°C for 20 min, the
supernatant was extracted and protein concentrations
were measured (Pierce, Rockford, IL). For coimmunopre-
cipitation experiments, solubilized striatum/cell extracts
(500 to 700 μg of protein) were incubated in the presence
of primary antibodies anti-CPE (Chemicon, B.D Trans-
duction Laboratories™), anti-DAT (Santa Cruz Biotech-
nology, Santa Cruz, CA), or rabbit IgG (1 to 2 μg) for 4 hr
at 4°C, followed by the addition of 20 μl of protein A/G
agarose (Santa Cruz Biotechnology, Santa Cruz, CA) for
12 hr at 4°C. Pellets were washed four times in the buffer
described above, boiled for 5 min in SDS sample buffer,
and subjected to SDS-PAGE. In each experiment 20 to 50
μg of tissue-extracted protein was used as control. For
affinity purification experiments the solubilized striatum
extracts (50–100 μg of protein) were incubated with glu-
tathione-Sepharose beads (Pharmacia, Dorval, Québec,
Canada) bound to the indicated GST-fusion proteins (50
to 100 μg) at 4°C for 12 hr. Beads were washed three
times with 600 μl of PBS containing 0.1–0.5% Triton X-
100 before the bound proteins were eluted with glutath-
ione elution buffer. Elutes were incubated in sample
buffer and subjected to SDS-PAGE for Western blot anal-
ysis. Blots were blocked with 5% nonfat dried milk dis-
solved in TBST buffer (10 mM Tris, 150 mM NaCl, and
0.1% Tween-20) for 1 hr at room temperature, washed
three times with TBST buffer, and then incubated with the
appropriate primary antibody (anti-DAT or anti-CPE,
diluted in 1% milk in TBST) overnight at 4°C and washed
again with TBST buffer three times; the membrane was
incubated with horseradish peroxidase-conjugated sec-
ondary antibody (diluted in 1% milk in TBST; Sigma) for
1.5 hr at room temperature. The proteins were visualizedMolecular Brain 2009, 2:10 http://www.molecularbrain.com/content/2/1/10
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with enhanced chemiluminescence reagents as described
(Amersham Biosciences).
In vitro binding assay
A probe was made with CPE subcloned into mammalian
expression vector pCDNA3 using TNT® T7 Quick Coupled
Transcription/Translation System (Promega, Madison,
WI) and [35S] methionine (PerkinElmer, Waltham, MA).
Glutathione beads carrying 20 μg GST-DAT-NT, GST-
DAT-CT or GST alone were incubated at room tempera-
ture for 1 hour with [35S] methionine-labeled CPE probe,
respectively. The beads were then washed six times with
PBS containing 0.1–0.5% (V/V) Triton X-100 and eluted
with 10 mM glutathione elution buffer. Eluates were sep-
arated by SDS-PAGE and visualized by autoradiography
using BioMax (Kodak) film.
[3H] Dopamine uptake analysis and [3H] WIN binding
We measured dopamine uptake on intact cells as
described previously [18]. Two to 4 days after transfection
in 24-well plates (~2 × 105 cells seeded per well), medium
was removed and wells were rinsed with 0.5 ml of uptake
buffer (5 mM Tris, 7.5 mM HEPES, 120 mM NaCl, 5.4
mM KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 1 mM ascorbic
acid, 5 mM glucose, pH7.1). Cells were then preincubated
in duplicate with the indicated concentrations of
dopaminergic agents (10-13 to 10-4M) 5 min before the
addition of 0.25 ml of 20 nM [3H]dopamine (final con-
centration) and incubated for 10 min at room tempera-
ture in a total volume of 0.5 ml. Nonspecific [3H]
dopamine (37–53 Ci/mmol) uptake was defined in the
presence of 10 μM GBR-12909. Wells were rinsed twice
with 0.5 ml of uptake buffer; cells were solubilized in 0.5
ml of 1%SDS and collected to measure incorporated radi-
oactivity using a Beckman liquid scintillation counter (LS
6000SC). For [3H] WIN binding, the differences from
uptake are using [3H] WIN (4 nM final concentration) and
incubating for 2 to 3 h at 4°C before adding 1% SDS.
Cell-ELISA assays
Cell-ELISA assays (colorimetric assays) were done essen-
tially as previously described [22,29]. HEK-293 cells were
transiently transfected with the indicated cDNA constructs
by the Lipofectamine method (6–10 μg of each indicated
cDNA per 7.5 × 106 cells), distributed equally to two six-
well plates (35 mm/well), and grown for 2–4 d. The
cotransfected cells were fixed in 2% paraformaldehyde for
10 min in the absence (nonpermeabilized conditions) or
the presence (permeabilized conditions) of 1% TritonX-
100. Cells were incubated with anti-DAT (Chemicon) for
the purpose of labeling the receptors on the cell surface
under nonpermeabilized conditions or the entire receptor
pool under permeabilized conditions. After incubation
with the corresponding horseradish peroxidase (HRP)-
conjugated secondary antibodies (Sigma), the HRP sub-
strate o-phenylenediamine (OPD; Sigma) was added to
produce a color reaction that was stopped with 3 N HCl.
The cell surface and total expression of DAT was presented
as the colorimetric readings under nonpermeabilized and
permeabilized conditions and then normalized to the
control groups (transfected with DAT alone) respectively.
Pulse-Chase analysis
HEK 293 T cells were transiently transfected with DAT or
together with CPE, grown to near-confluency over 12 hr,
pre-incubated in extracellular solution (7 mM HEPES,
121 mM NaCL, 3 mM NaHCO3, 1 mM Na-pyruvate, 1.8
mM CaCL2, 20 mM glucose, 0.01 mM glycine, 5 mM
KCL), for 1 h at 37°C, and labeled in fresh medium con-
taining 0.2 mCi/ml promix [35S] methionine/cysteine
(Amersham Biosciences). After incubation for a further 4
h at 37°C, the pulse was terminated by washing cells twice
and incubating with MEM (supplemented with 10% FBS)
for the indicated times. Immunoprecipitation of DAT was
carried out.
Cell culture and confocal imaging
After tranfection (as above) for 2–4 d, HEK-293 cells were
used for double-label immunoconfocal microscopy. CPE
mouse Abs (Pharmacia) and DAT Rabbit Abs (Santa Cruz)
were used as primary antibodies in overnight incubations
at 4°C and detected using secondary antibodies (Sigma)
conjugated to FITC or Cy3 fluorophores. Control cells in
which no primary Ab was included did not reveal any
immunoreactive staining.
GST fusion proteins and mini-gene
DAT CT cDNA-encoding fragment was amplified by PCR
from full-length cDNA clones [18]. DAT CT and DAT NT
GST-fusion proteins were prepared from bacterial lysates
as described by the manufacturer (Amersham Bio-
sciences). To confirm appropriate splice fusion and the
absence of spurious PCR-generated nucleotide errors, we
resequenced all constructs.
Acute Rat Striatum slices
Acute hippocampal slices (350 μm) were prepared from
Sprague-Dawley rats using a McIlwain tissue chopper
(Mickle Laboratory Engineering, Gomshall, UK). Under
deep anesthesia, brains were rapidly removed and stria-
tum was dissected out and leave for 5 mins in ice-cold arti-
ficial cerebrospinal fluid (ACSF) containing (mM) NaCl,
126; KCl, 2.5; MgCl2, 1; CaCl2, 1; KH2PO4, 1.25;
NaHCO3, 26; and glucose, 20 that was bubbled continu-
ously with carbogen (95%O2/5%CO2) to adjust the pH
to 7.4. Freshly cut slices were placed in an incubating
chamber with carbogenated ACSF and recovered from
stress at 37°C for 1 hr. Slices were then treated with/with-
out PMA for 30 mins and harvested for Co-immunopre-
cipitation and Western blotting analysis.Molecular Brain 2009, 2:10 http://www.molecularbrain.com/content/2/1/10
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Results
DAT CT directly interacts with CPE
To search for DAT-interacting proteins, we employed the
entire DAT-CT as bait to screen a human substantia nigra
library using the yeast two-hybrid system (Fig 1A). Inter-
acting clones were selected on Leu-/Trp- media. Of the
158 colonies growing under this selection, 35 were posi-
tive for lacZ expression. Sequence analysis revealed that 2
of the 3 clones were fragments of CPE, which was previ-
ously described as a sorting receptor to target prohor-
mones to the secretory granules of the regulated secretory
pathway in neuroendocrine cells [30].
To further confirm the interaction between DAT and CPE,
we performed GST affinity pull down assay using purified
GST fusion peptides containing sequences from DAT-CT
(GST-DAT-CT). The results shown in Fig. 1B demon-
strated that GST-DAT-CT could selectively precipitate CPE
from solubilized rat striatal tissue whereas GST alone was
unable to purify CPE. Moreover, to exclude the possibility
of CPE non-specifically binding to GST fusion peptides,
intracellular N-terminal domain of DAT was also
employed as a control. As shown in Fig 1B, GST-DAT-NT
was unable to precipitate CPE, strongly suggesting that the
interaction between DAT and CPE is mediated specifically
by the DAT-CT. While these results demonstrate the pres-
ence of the DAT: CPE protein complex in rat striatal tissue,
it does not clarify whether the DAT: CPE protein complex
is formed through a direct interaction or is mediated indi-
rectly by an accessory binding protein. In vitro binding
assays were performed to provide evidence that DAT and
CPE can directly interact with each other. As shown in Fig-
ure 1C, in vitro translated [35S]-CPE probe hybridized with
GST-DAT-CT but not GST-DAT-NT or GST alone, indicat-
ing the specificity of the direct protein-protein interaction
between CPE and DAT-CT. Taken together, these data sug-
gest that CPE is involved in a direct protein-protein inter-
action with DAT-CT.
Next, we examined in solubilized rat striatum, whether
DAT could coimmunopreicipiate with CPE thus provid-
ing additional evidence of a physical association between
DAT and CPE. As illustrated in Fig. 1D, CPE antibodies co-
precipitated a protein with a relative molecular mass of 83
kDa that immunoreacted with DAT antibodies. Taken
together, these results showed that DAT could associate
with CPE via the DAT-CT.
Coexpression CPE and DAT increased the Vmax of DAT 
without effects on its affinity
DAT plays a determinant role in dopaminergic neuro-
transmission by rapidly removing released dopamine
from the synaptic cleft. To explore the functional impor-
tance of the DAT-CPE interaction, we examined the DAT-
mediated DA uptake activity in HEK-293 cells coexpress-
ing CPE. As illustrated in Fig 2A, CPE coexpression signif-
icantly increased the maximal uptake velocity (Vmax) of
[3H] DA by ~50% (DAT: Vmax = 10.8 ± 1 pmol/min/well;
DAT+CPE: 16 ± 1.9 pmol/min/well; P < 0.01), whereas no
significant change in the estimated Km of the DAT could
be observed (DAT: Km = 6.6 ± 0.7 μM in cells expressing
DAT vs 6.7 ± 1.6 μM in cells expressing DAT and CPE). To
further exclude the possibility that Vmax differences
might result from the affinity changes, we performed [3H]
WIN 35,428 competitive binding assay. As depicted in Fig.
2C and 2D, the estimated affinity of DA at the ligand
binding site of DAT in CPE coexpressing cells was not sig-
nificantly different from that observed for cells expressing
DAT alone (IC50 = 986 ± 24 nM in cells expressing DAT vs
1001 ± 87 nM in cells expressing DAT and CPE). The effect
of CPE on DAT was not restricted to HEK-293 cells but
was also seen in COS-7 and Ltk- cells (data not show).
Next, to confirm that the selective increase in maximal
DAT-mediated DA uptake resulted from DAT-CPE interac-
tion, we tested whether a minigene (MG) encoding
sequences of the DAT-CT could block these effects, since
coexpressioin of CT tail peptide would act as a competi-
tive inhibitor to the CPE-DAT interaction. As described in
Fig. 2B, DAT-CT tail583–620 MG cotransfected with DAT
alone did not change either the Km or Vmax of cellular
[3H] DA uptake. However, coexpression of the MG encod-
ing the peptide DAT-CT583–620 significantly inhibited
the increasing effects of DAT-mediated DA translocation
by CPE. Taken together, these data indicated that the
binding of DAT-CT tail583–620 sequences to CPE was
both sufficient and necessary for the expression of CPE-
mediated functional regulation of the DA translocation
process.
Regulation of DAT expression and trafficking by CPE
Since no change in DA uptake affinity could be observed
upon coexpression of CPE with DAT, the increase in Vmax
may reflect a change in the population of cell surface DAT.
Therefore, we next examined if DAT cell surface expres-
sion levels change upon coexpression of CPE by using a
cell-based ELISA assay to quantify changes at the cell sur-
face and total DAT levels [27-29]. As shown in Fig 3, coex-
pression of CPE increased the levels of both total DAT and
cell surface DAT to about ~20% (Fig. 3A, B).
To directly examine the cellular effects of CPE on DAT, we
analyzed subcellular localization of DAT and CPE in
transfected HEK-293 cells using confocal immunofluores-
cence microscopy. The results showed that DAT and CPE
displayed disperse distribution patterns when expressed
separately in HEK-293 cells. DAT could be found both at
the cell surface and within cell, whereas CPE located
throughout the cytoplasm (Fig. 3A, B). However, when
CPE and DAT were cotransfected in HEK-293 cells, theMolecular Brain 2009, 2:10 http://www.molecularbrain.com/content/2/1/10
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Figure 1 (see legend on next page)
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distribution pattern of each protein changed dramatically,
with almost completely overlapping distribution at cell
surface, as revealed by the merged confocal immunofluo-
rescence images (Fig. 3C). In virtually all cells coexpress-
ing DAT and CPE, DAT was largely found at the plasma
membrane and colocalized with CPE (Fig. 3C). These data
suggested that CPE modulated DAT via a posttranslational
mechanism, which possibly included reduced degrada-
tion of surface DAT.
Cell surface DAT may derive from newly synthesized DAT
or from recycled DAT that have been re-inserted into the
membrane after being internalized. Thus, changes in both
cell surface and total DAT levels may reflect changes in
DAT protein turnover rates in the presence of CPE. To test
this possibility, we carried out pulse-chase studies to
examine DAT protein half-life in the presence of CPE. As
showed in Fig. 3D, in the absence of CPE, the DAT-posi-
tive band was prominent at 6 hours but began to disap-
pear at 12 hours and was completely absent at 24 hours.
However, coexpression of CPE inhibited the disappear-
ance of the DAT-positive band at 12 hours but was still
completely degraded at 24 hours.
CPE stablized DAT via reducing the phosphorylation state 
of DAT
Cell surface expression and degradation of DAT [31] is
modulated by various cellular signals, substrates and neu-
ronal activity. Among them, the best characterized form of
DAT regulation is phosphorylation [32]. Previous reports
show that protein kinase C (PKC) down-regulates trans-
porter activity via internalization of DAT in several sys-
tems including striatal synaptosomes [33,34], slices [35]
and heterologous cells [31,36,37]. Thus, the increased sur-
face expression of DAT by CPE may involve phosphoryla-
tion events. To explore this possibility, we first tested
whether CPE had any effect on the phosphrylation levels
of DAT. As illustrated in Fig. 4A, using an antibody that
detected phosphorylated serines, immunoprecipitation of
DAT from COS-7 cells revealed a decrease in serine phos-
phorylation in cells coexpressing CPE. Reduced phospho-
rylation state of DAT might reflect that association of CPE
with DAT leaded to the occlusion of PKC phosphorylation
sites. We then examined the association between CPE and
DAT under various phosphorylation conditions. Rat stria-
tum slices were treated with a PKC activator, phorbol 12-
myristate 13-acetate (PMA) for 30 min before immuno-
precipitation with the CPE antibody. As shown in Fig 4B,
PMA treatment reduced the association between CPE and
DAT as compared with non-treated COS-7 cells, implying
that CPE preferentially interacted with non-PKC phos-
phorylated forms of DAT.
CPE modulated the function of DAT through surface 
phosphorylation and expression
To provide further evidence that the expression and func-
tional affects on DAT were mediated by phosphorylation
changes induced by the CPE-DAT interaction, we explored
the relationship of DAT phosphorylation with DA translo-
cation velocity and surface expression under phosphor-
ylating conditions mentioned above. As depicted in Fig
5A, PMA treatment significantly reduced the increasing
effects of CPE on DAT-induced DA translocation velocity.
Moreover, the changes of Vmax levels coincided with both
the total and surface expression levels of DAT (Fig 5B);
strongly suggesting that PMA reduced the effects of CPE
probably through increased internalization via phosphor-
ylation.
Discussion
Recent studies have identified new properties of the DAT,
including the regulation of cell excitability through leak
current conductance and channel mechanism [38,39], as
well as serving as a pathway for substrate-induced
dopamine release at both axonal and dendritic sites [40].
However, each cellular role currently associated with the
DAT depends on plasma membrane expression. In the
present study, we provided biochemical evidence for a
physical interaction between CPE and DAT via the DAT-
CT. We have shown that this interaction leads to cell sur-
Association of DAT with CPE Figure 1 (see previous page)
Association of DAT with CPE. A, Using the Yeast 2-Hybrid System 3 (Invitrogen), 1.7 × 106 independent clones of a 
human substantia nigra library (in pGAD10) were screened using DAT-NT, containing the amino terminus up to the first trans-
membrane domain (TM1) and DAT-CT, containing the entire carboxyl terminus after the 12th transmembrane domain (TM12) 
as baits. Interacting clones were selected on media lacking Leu, Trp, and His, in the presence of 2.5 mM 3-AT. Of 158 colonies 
growing under this selection, 35 were positive for lacZ expression. Sequence analysis of these clones showed that two of them 
represented fragments of carboxypeptidase E (CPE). One clone showing very strong lacZ expression encoded a portion of 
CPE beginning at amino acid residue 123 of the mature protein. No interaction was observed between CPE construct and Gal4 
BD fused to murine p53 or human lamina C or between any of the DAT-BD fusions and Gal4 AD fused to SV40 large T anti-
gen. B, GST fusion protein precipitation assay using the complete C and N terminus of DAT fused to GST. Aliquots containing 
GST fusion fragments were incubated with rat striatal extracts and analyzed by Western blot using a polyclonal anti-CPE anti-
body. C, Using an in vitro binding assay, [35S]-CPE probe bound with GST-DAT-CT, but not with GST-DAT-NT or GST alone. 
D, DAT coimmunoprecipitated with CPE antibodies from rat striatal extracts.Molecular Brain 2009, 2:10 http://www.molecularbrain.com/content/2/1/10
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CPE-mediated enhancement of [3H] DA uptake Figure 2
CPE-mediated enhancement of [3H] DA uptake. A, Representative saturation plots of [3H]DA uptake in HEK-293 cells 
expressing the DAT alone or coexpressing-CPE revealed an increase in the Vmax for [3H] DA uptake accumulation (n = 9, P < 
0.01) with no significant alteration in estimated Km values (listed in the text). B, CPE-mediated increase in [3H] DA uptake by 
DAT was blocked with the coexpression of a minigene encoding the DAT-CT583–620 peptide but did not alter the uptake of 
cells expressing DAT alone (n = 4, P < 0.01). C, Representative curves of the dose-dependent inhibition of [3H] WIN (4 nM) 
binding by dopamine to DAT. Coexpression of CPE and DAT did not alter the estimated affinity value of dopamine for DAT 
(IC50 values listed in the text). D, Estimated IC50 values in control or CPE coexpressing cells. Values represent the means ± 
SEM of 3–9 independent experiments, each conducted in duplicate. Data were analyzed by ANOVA, followed by post hoc Stu-
dent-Newman-Keuls test. **, P < 0.01 compared with the group cotransfected with DAT and pcDNA3; ##, P < 0.01 compared 
with the group cotransfected with DAT and CPE.
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Figure 3 (see legend on next page)
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face stabilization of DAT via reduced degradation, possi-
bly through a reduction in DAT phosphorylation. In
addition, immunofluorescence analysis demonstrated
that co-expression of CPE and DAT facilitated surface
translocation of both proteins. Functional assays showed
that the increased surface DAT led to a corresponding
increase in DA uptake but had no effect on DAT affinity
for DA. Finally, mini-gene encoding the DAT CT blocked
CPE's effects. We concluded that CPE-mediated modula-
tion of DAT trafficking, membrane expression and phos-
phorylation was facilitated by the CPE-DAT physical
coupling.
The present finding highlighted the importance of CPE in
trafficking and metabolic processing of DAT. DAT under-
goes cyclical traffic to and from the plasma membrane
and changes in transporter surface presentation can result
from modulating endocytosis, recycling or de novo bio-
synthesis. Coexpression of CPE with DAT changed the dif-
fuse DAT expression throughout the cell to stronger
plasma membrane localization and suggests the interac-
tion occur intracellularlly. CPE exists in both a soluble
form and a membrane form [41,42]. Soluble forms of
CPE function as an exopeptidase to cleave proneuropep-
tides within the lumen of the vesicle and yield biologically
active peptides [43,44], whereas membrane from of CPE
is associated with lipid rafts and exist in a transmembrane
orientation in secretory granules as a sorting receptor [45].
During proteolytic processing of peptide precursor, CPE
normally removes the C-terminal basic residues on the
processing intermediates after the action of prohormone
convertases on the peptide precursor [46]. In many cases,
as a final step in the biosynthesis of neuropeptides, CPE
recognizes and cleaves the Arg/Lys paired basic residues at
the COOH-terminal side to generate the final neuropep-
tide. Thus, the exact nature of CPE-DAT association, how
and where this interaction takes place intracellularly
remains to be determined.
Although not in paired form, Arg/Lys residues are also
present in the C-terminus of hDAT, rendering the possi-
bility that CPE would be involved in the processing of
DAT. Interestingly, CPE band did show a slightly lower on
pulse-chase assay coexpressed with DAT, which deserved
further investigation. Immunogold labeling detects DAT
in tubulo-vesicular structures and small electron-lucent
vesicles in dopaminergic neurons from the dorsal stria-
tum and nucleus accumbens [8-10]. Also, both ultrastruc-
tural and biochemical studies revealed the localization of
DAT in endosomes and tubulo-vesicular membranes but
not biosynthetic machinery, suggesting that most of intra-
cellular DAT- positive vesicles are endocytic but not secre-
tory [14,37]. Interestingly, the membrane form of CPE has
been demonstrated to bind to POMC [30] and BDNF
[41], sorting these precursors at the trans-Golgi network
(TGN) into vesicles of the regulated secretory pathway in
pituitary cells and hippocampal neurons, respectively.
Previous results show that secretory and endocytic path-
ways converge forming the TGN, an intricate system of
tubulovesicular membranes, the main site for sorting
secretory vesicles and transports proteins including DAT
[9,11,47,48] and for specifically targeting synaptic mem-
brane receptors into dendrites [49]. Moreover, the TGN is
known to interact with the recycling endosomal system in
hippocampal neurons [50]. Thus, the co-localization of
these two proteins in TGN may be the potential site where
the CPE-DAT interaction occurs.
DAT possesses consensus sequences for phosphorylation
by protein kinases [6,13,51,52] including cAMP-depend-
ent protein kinsase, protein kinase C (PKC), Ca2+/cal-
modulin-dependent protein kinase, MAP kinase and
tyrosine kinase. Several studies have shown that regula-
A, Summarized data indicating effects of CPE on DAT membrane expression in cotransfected HEK-293 cells Figure 3 (see previous page)
A, Summarized data indicating effects of CPE on DAT membrane expression in cotransfected HEK-293 cells. 
Columns show the means ± SEM of the ratios of colorimetric readings under coexpression of DAT and pcDNA3 conditions 
versus coexpression of DAT and CPE. **P < 0.01, n = 3 (Student's t test). B, Summarized data indicating effects of CPE on 
DAT total expression including the extracellular and intracellular ones in cotransfected HEK-293 cells. Columns show the 
means ± SEM of the ratios of colorimetric readings under coexpression of DAT and pcDNA3 conditions versus coexpression 
of DAT and CPE. **P < 0.01, n = 3 (Student's t test). C, CPE colocalizes with DAT in HEK-293 cells. The distribution pattern 
of DAT and CPE when expressed individually or coexpressed in HEK-293 cells are shown. Immunostaining was performed 
using the rabbit anti-DAT or the mouse anti-CPE antibodies and secondary antibodies:CY3 anti-mouse (red) and FITC-conju-
gated anti-rabbit antibodies (green). Yellow staining on the merged panels depicted colocalization. No staining was observed 
when primary antibodies were eliminated. Data are representative of 4–6 independent experiments, with a total cell sampling 
of more than 1000. D, Measurement of DAT protein metabolism by labeling with radioactive amino acids. HEK-293 cells, into 
which the indicated genes had been transfected, acutely incorporated 0.2 mCi/ml promix [35S]-methionine/cysteine for 4 h and 
were grown in the complete medium for further 6, 12 and 24 h. DAT protein was immunoprecipitated from the total protein 
by an anti-DAT polyclonal antibody. The antigen-antibody complex was further analyzed on polyacrylamide gel and autoradiog-
raphy was performed. The results were repeated 3 times.Molecular Brain 2009, 2:10 http://www.molecularbrain.com/content/2/1/10
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tion of kinase activity in striatal synaptosomal prepara-
tions and heterologous cell expression systems affects
DAT uptake activity [12], which is believed to result from
a rapid redistribution of transporter from the cell mem-
brane to intracellular compartments, rather than changes
in the intrinsic transport activity [31,37,53,54]. This phos-
phorylation/dephosphorylation status is closely coupled
to DAT endocytic trafficking and interestingly PKC activa-
tion has been shown to decrease DAT activity through
clathrin-mediated endocytosis [31,55], an event associ-
ated with an increase in DAT phosphorylation [52]. This
is in agreement with our studies in which CPE decreases
DAT phosphorylation leading to slower degradation and
increase cell surface localization. However, there have
been reports that PKC-induced phosphorylation of the
DAT itself is not required for PKC-induced DAT sequestra-
tion [56], leading to the possibility that DAT are trapped
in its phosphorylated state in subcellular compartment,
where CPE may speed up the assorting and recycling back
to the membrane of the internalized DAT.
The exact mechanism for CPE's effects on DAT phosphor-
ylation and its relationship with cell surface DAT expres-
sion require further investigation. Foster and colleagues
recently report that the amino terminus of DAT, which
contains a cluster of serine residues, is the primary site of
phosphorylation by PKC [35]. It is possible that the inter-
action with CPE may mask the PKC phosphorylation site
on DAT. Indeed, it has been proposed that transporter-
interacting proteins might directly or indirectly regulate
kinase-dependent effects on DAT activity [57]. Alterna-
tively, there is evidence that PKC- mediated functional
regulation of DAT is not achieved by direct phosphoryla-
tion of the DAT protein [58], as has been demonstrated
for the GABA transporter, where PKC down regulates
transporter function by modulating the association of
syntaxin with the transporter [59]. Moreover, other yet-to-
be-identified proteins may also play a role in regulating
DAT function. Blakely and colleagues found that the pro-
tein phosphatase 2A (PP2A) could be co-immunoprecipi-
tated from brain tissue with DAT, NET, or SERT proteins
[60]. In the case of SERT, the interaction with PP2A was
dynamically regulated by phosphatase inhibition, PKC
activation and transporter substrates. Although it is not
known whether PP2A binds directly to monoamine trans-
Figure 4
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CPE affects the phosphorylation state of DAT Figure 4
CPE affects the phosphorylation state of DAT. A, 
COS-7 cells were transiently transfected with DAT or 
together with CPE by using electroporation, grown for 3–4 
days, and was collected to be homogenized. The cells lysates 
was immunoprecipitated with anti-DAT antibody overnight. 
Subsequent western blotting of SDS-PAGE immunoprecipi-
taed samples with polyclonal anti-phosphoserine antibody 
and reimmunoblotting the membrane with anti-DAT anti-
body. B, Phosphorylation state of DAT affected the interac-
tion between DAT and CPE. Striatal slices were pretreated 
for 30 min with 2 μM PMA before immunoprecipitation with 
the DAT antibody. Subsequent western blotting of SDS-
PAGE immunoprecipitaed samples were incubated with anti 
DAT or anti CPE antibody.Molecular Brain 2009, 2:10 http://www.molecularbrain.com/content/2/1/10
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CPE reserves PKC-mediated inhibition of DAT uptake and cell surface expression Figure 5
CPE reserves PKC-mediated inhibition of DAT uptake and cell surface expression. A, Uptake of [3H] DA in HEK-
293 cells after a 30-min incubation at 37°C with vehicle alone (uptake buffer) or 2 μM PMA. Values are the percentage of 
uptake activity compared with untreated cells ± SEM. Data were analyzed by ANOVA, followed by post hoc Student-Newman-
Keuls test. **, P < 0.01 compared with the group cotransfected with DAT and pcDNA3; ##, P < 0.01 compared with the group 
cotransfected with DAT and CPE untreated with PMA, n = 3. B, Summarized data indicating effects of CPE on DAT membrane 
expression in cotransfected HEK-293 cells after 30-min incubation at 37°C with vehicle alone (uptake buffer) or 2 μM PMA. 
Columns show the means ± SEM of the ratios of colorimetric readings. Data were analyzed by ANOVA, followed by post hoc 
Student-Newman-Keuls test. **, P < 0.01 compared with the group cotransfected with DAT and pcDNA3; ##, P < 0.01 com-
pared with the group cotransfected with DAT and CPE untreated with PMA, n = 3.
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porters, this association might help to explain the molec-
ular events that are responsible for transporter
phosphorylation and internalization
Conclusion
Taken together, data from our present study and previous
reports indicate that protein-protein interactions appear
to be important for DAT function. The association of DAT
with CPE may have critical impact on DAT phosphoryla-
tion state and be involved in cyclic trafficking. While our
findings shed new light on the trafficking mechanisms of
DAT, several questions still remain to be addressed. It
remains to be determined in which cellular compartment
this interaction occurs and the details of mechanisms
involved that may regulate the CPE-DAT interaction. Fur-
thermore, both CPE and the DAT may have roles in obes-
ity and it will be interesting to investigate if this
interaction contributes to the pathophysiology of this dis-
ease. Further investigation into characterizing this interac-
tion and understanding the regulatory factors involved,
will lead to a better understanding of DAT trafficking and
may have important physiological and pathophysiologi-
cal implications.
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